Novo, Novartis, BMS and J&J win judge's blessing to combine arguments in upcoming IRA hearing

Four major drugmakers are joining forces as they prepare to battle certain aspects of the Inflation Reduction Act (IRA) in court next month.

Tuesday, a federal judge in New Jersey agreed to let Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson present oral arguments together in their bid to challenge the IRA’s Medicare negotiations framework, which will allow Medicare to bargain over the costs of certain drugs beginning in 2026.